# Zirconium-89

Source: https://nuclide.cc/isotopes/zr-89/  
Nuclide record `zr-89` (Isotope). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A radioactive metal that lasts about three days, long enough to attach to a whole antibody and follow it around the body for several days on a PET scan, which is why it underpins 'immuno-PET'.

## Summary

Zirconium-89 decays with a 78.4-hour (3.3-day) half-life, mostly by electron capture (about 77%) and partly by positron emission (about 23%), to metastable yttrium-89, which promptly emits a 909 keV gamma. That three-day half-life is the reason 89Zr is the default radiometal for immuno-PET: intact monoclonal antibodies take two to four days to reach optimal tumour-to-background ratios in vivo, far longer than any conventional PET isotope survives, but well matched to zirconium-89's decay.

It is made almost entirely by cyclotron bombardment of a solid yttrium-89 target, 89Y(p,n)89Zr; because yttrium-89 is 100% naturally abundant the target needs no isotopic enrichment, which keeps production comparatively simple and inexpensive, though proton energy has to be kept below about 13 MeV to avoid the long-lived 88Zr impurity. After irradiation, 89Zr is purified on a hydroxamate resin and conjugated to antibodies through chelators such as desferrioxamine (DFO) or newer macrocyclic cages designed to resist the free-zirconium bone uptake that DFO-based constructs can show over several days.

In the Nuclide graph, 89Zr's main current oncology use is CAIX PET with 89Zr-girentuximab in renal cell carcinoma, which forms an emerging diagnostic-therapeutic pair with 177Lu- or 225Ac-labelled girentuximab.

## Fields

- Kind: Isotope
- Status: emerging
- Last checked: 2026-09-22
- Also known as: 89Zr
- Tags: positron emitter; immuno-PET; long-lived PET

## Sources

- Springer: clinical nuclear medicine applications of zirconium-89 immuno-PET: https://link.springer.com/article/10.1186/s41181-025-00418-8
- EJNMMI Radiopharmacy & Chemistry: good practices for 89Zr production: https://ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-024-00258-y

## Connected records

- drugs: [Zirconium-89 girentuximab](https://nuclide.cc/drugs/girentuximab-zr89/)
- indications: [Renal cell carcinoma](https://nuclide.cc/indications/rcc/)
- technologies: [Automated synthesis modules](https://nuclide.cc/technologies/automated-synthesis-modules/), [CAIX PET (89Zr-girentuximab)](https://nuclide.cc/technologies/caix-pet/), [Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)](https://nuclide.cc/technologies/cyclotron-isotope-production/), [HER2 PET](https://nuclide.cc/technologies/her2-pet/), [Immuno-PET](https://nuclide.cc/technologies/immuno-pet/), [Medical cyclotrons, hot cells, and synthesis modules](https://nuclide.cc/technologies/medical-cyclotrons-synthesis-modules/), [PET (positron emission tomography)](https://nuclide.cc/technologies/pet/), [TROP2 PET](https://nuclide.cc/technologies/trop2-pet/)
- companies: [Telix Pharmaceuticals](https://nuclide.cc/companies/telix/)
- pathways: [VHL / HIF oxygen sensing](https://nuclide.cc/pathways/hif-vhl/)
- trials: [89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study](https://nuclide.cc/trials/nct06750419/), [An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma](https://nuclide.cc/trials/nct03533283/), [ZIRCON](https://nuclide.cc/trials/zircon/)
- ideas: [CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy](https://nuclide.cc/ideas/idea-caix-theranostics/), [CD8 PET to stop or switch immunotherapy early](https://nuclide.cc/ideas/idea-cd8-pet-io/), [Total-body PET for personalised radioligand dosing](https://nuclide.cc/ideas/idea-total-body-pet-dosimetry/), [TROP2 PET to choose and sequence TROP2 ADCs](https://nuclide.cc/ideas/idea-trop2-pet-selection/)
- people: [Jason S. Lewis](https://nuclide.cc/people/jason-lewis/)
- opportunities: [CAIX imaging of the indeterminate renal mass](https://nuclide.cc/opportunities/opp-caix-indeterminate-renal-mass/), [DLL3 imaging for small-cell lung cancer](https://nuclide.cc/opportunities/opp-dll3-imaging-sclc/), [HER3 imaging, and why three tracers stalled](https://nuclide.cc/opportunities/opp-her3-imaging-crossover/)
- fronts: [Radiochemistry & manufacturing](https://nuclide.cc/fronts/f-radiochemistry/)
- key papers: [ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma](https://nuclide.cc/key-papers/paper-zircon-lancet-oncol-2024/)
- targets: [5T4 (trophoblast glycoprotein)](https://nuclide.cc/targets/tpbg-5t4/), [HER3 (ERBB3)](https://nuclide.cc/targets/her3/), [Mesothelin (MSLN)](https://nuclide.cc/targets/mesothelin/), [Sortilin (SORT1)](https://nuclide.cc/targets/sortilin/)
- terms: [Specific activity and molar activity](https://nuclide.cc/terms/specific-activity/), [Theranostic pair](https://nuclide.cc/terms/theranostic-pair-term/)

---
JSON: https://nuclide.cc/api/v1/entities/zr-89.json